All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $5,095 | $3,714 | $2,248 | $1,828 | $1,037 | $844 |
| Cost of Revenue | $1,125 | $677 | $307 | $268 | $140 | $115 |
| Gross Profit | $3,970 | $3,037 | $1,942 | $1,560 | $897 | $729 |
| General & Administrative | $1,337 | $1,211 | $976 | $796 | $771 | $621 |
| Research & Development | $1,553 | $1,320 | $1,126 | $1,004 | $883 | $792 |
| Total Operating Expenses | $4,018 | $3,212 | $2,425 | $2,110 | $1,822 | $1,553 |
| Operating Income | $1,077 | $502 | -$177 | -$282 | -$785 | -$709 |
| Non-Operating | ||||||
| Net Interest Expense | -$205 | -$141 | -$20 | -$26 | -$131 | -$141 |
| Other Non-Operating Income (Expense) | $7 | -$37 | -$181 | -$126 | -$211 | -$2 |
| EBT (Earnings Before Tax) | $880 | $323 | -$377 | -$434 | -$1,127 | -$852 |
| Income Tax Expense | -$1,896 | $9 | -$99 | $7 | $4 | $1 |
| Net Income | ||||||
| Net Income | $2,775 | $314 | -$278 | -$440 | -$1,131 | -$853 |
| Per Share Data | ||||||
| Revenue Per Share | $36.91 | $27.58 | $17.61 | $14.64 | $8.53 | $7.13 |
| EPS (Basic) | $20.80 | $2.39 | -$2.18 | -$3.52 | -$9.30 | -$7.20 |
| EPS (Diluted) | $20.25 | $2.33 | -$2.18 | -$3.52 | -$9.30 | -$7.20 |
| Weighted Avg Shares (Basic) | 133.8M | 131.0M | 127.7M | 124.9M | 121.7M | 118.5M |
| Weighted Avg Shares (Diluted) | 138.0M | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M |
| Shares Outstanding | 138.0M | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M |
Alnylam Pharmaceuticals (ALNY) financials: revenue, profit and margins
Alnylam Pharmaceuticals (ALNY) generated about n/a in revenue and $2.7 billion in net income (a 8.4% net margin) over the trailing twelve months, growing at roughly 49.8% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Alnylam Pharmaceuticals profitable?+
Yes, Alnylam Pharmaceuticals reported about $2.7 billion in net income over the trailing twelve months, a net profit margin of roughly 8.4%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Alnylam Pharmaceuticals's profit margins?+
Alnylam Pharmaceuticals runs a gross margin of about 81.8%, an operating margin of about 13.5%, a net margin of about 8.4%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Alnylam Pharmaceuticals growing?+
Alnylam Pharmaceuticals's revenue has compounded at roughly 49.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ALNY's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 23 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 30 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with ALNY
Held by ETFs
ALNY is in 235 US ETFs. The largest of them, with ALNY's weight in each:
Vanguard Total Stock Market ETFVTI0.05%of the fund
Invesco QQQ Trust, Series 1QQQ0.17%of the fund
iShares Russell 1000 Growth ETFIWF0.09%of the fund
Spot a number that looks wrong? Check it in ALNY's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ALNY
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.